Evaluating heterogeneity of treatment effects

References

• Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34(6):585–612. doi: 10.1038/bjc.1976.220
   Google Scholar
• Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35(1):1–39. doi: 10.1038/bjc.1977.1
   Google Scholar
• Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn’t. Br Med J. 1996;312(7023):71–72. doi:10.1136/bmj.312.7023.71.
   Google Scholar
• Feinstein AR, Horwitz RI. Problems in the “evidence” of “evidence-based medicine.”. Am J Med. 1997;103(6):529–535. doi: 10.1016/S0002-9343(97)00244-1
   Google Scholar
• Black D. The limitations of evidence. J R Coll Phys Lond. 1998;32(1):23–26.
   Google Scholar
• Imai K, King G, Stuart EA. Misunderstandings between experimentalists and observationalists about causal inference. J Royal Statist Soc A Statist Soc. 2008;171(2):481–502. doi:10.1111/j.1467-985X.2007.00527.x.
   Google Scholar
• Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995;345(8965):1616–1619. doi: 10.1016/S0140-6736(95)90120-5
   Google Scholar
• Caplan LR. Evidence based medicine: concerns of a clinical neurologist. J Neurol Neurosurg Psychiatr. 2001;71(5):569–574. doi: 10.1136/jnnp.71.5.569
   Google Scholar
• Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine–reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189–2194. doi:10.1056/NEJMsr077003.
   Google Scholar
• Lagakos SW. The challenge of subgroup analyses–reporting without distorting. N Engl J Med. 2006;354(16):1667–1669. doi:10.1056/NEJMp068070.
   Google Scholar
• Sun X, Briel M, Walter SD, et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. Br Med J. 2010;340:c117, doi:10.1136/bmj.c117.
   Google Scholar
• Hayward RA, Kent DM, Vijan S, et al. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18, doi:10.1186/1471-2288-6-18.
   Google Scholar
• Brookes ST, Whitley E, Peters TJ, et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5(33):1–56. doi: 10.3310/hta5330
   Google Scholar
• Kent DM, Rothwell PM, Ioannidis JPA, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85, doi:10.1186/1745-6215-11-85.
   Google Scholar
• Hayward RA, Kent DM, Vijan S, et al. Reporting clinical trial results to inform providers, payers, and consumers. Health Aff Millwood. 2005;24(6):1571–1581. doi:10.1377/hlthaff.24.6.1571.
   Google Scholar
• Rothwell PM, Mehta Z, Howard SC, et al. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet. 2005;365(9455):256–265. doi:10.1016/S0140-6736(05)17746-0. doi: 10.1016/S0140-6736(05)70156-2
   Google Scholar
• Westover AN, Kashner TM, Winhusen TM, et al. A systematic approach to subgroup analyses in a smoking cessation trial. Am J Drug Alcohol Abuse. 2015;41(6):498–507. doi:10.3109/00952990.2015.1044605.
   Google Scholar
• Kent DM, Hayward RA, Griffith JL, et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med. 2002;113(2):104–111. doi: 10.1016/S0002-9343(02)01160-9
   Google Scholar
• Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists’ Collaborative group. Lancet. 1999;353(9170):2105–2110. doi: 10.1016/S0140-6736(98)11415-0
   Google Scholar
• Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287–2292. doi:10.1161/01.CIR.0000145172.55640.93.
   Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. HOT study group. Lancet. 1998;351(9118):1755–1762. doi: 10.1016/S0140-6736(98)04311-6
   Google Scholar
• Lopes AA, Andrade J, Noblat AC, et al. Reduction in diastolic blood pressure and cardiovascular mortality in nondiabetic hypertensive patients. A reanalysis of the HOT study. Arq Bras Cardiol. 2001;77(2):132–137. doi: 10.1590/S0066-782X2001000800004
   Google Scholar
• Baum A, Scarpa J, Bruzelius E, et al. Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial. Lancet Diabetes Endocrinol. 2017;5(10):808–815. doi:10.1016/S2213-8587(17)30176-6.
   Google Scholar
• Burke JF, Hayward RA, Nelson JP, et al. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes. 2014;7(1):163–169. doi:10.1161/CIRCOUTCOMES.113.000497.
   Google Scholar
• James KE, White RF, Kraemer HC. Repeated split sample validation to assess logistic regression and recursive partitioning: an application to the prediction of cognitive impairment. Stat Med. 2005;24(19):3019–3035. doi:10.1002/sim.2154.
   Google Scholar
• Lipkovich I, Dmitrienko A, Denne J, et al. Subgroup identification based on differential effect search–a recursive partitioning method for establishing response to treatment in patient subpopulations. Stat Med. 2011;30(21):2601–2621. doi:10.1002/sim.4289.
   Google Scholar
• Imai K, Ratkovic M. Estimating treatment effect heterogeneity in randomized program evaluation. Ann Appl Stat. 2013;7(1):443–470. doi:10.1214/12-AOAS593.
   Google Scholar
• Ruberg SJ, Chen L, Wang Y. The mean does not mean as much anymore: finding sub-groups for tailored therapeutics. Clin Trials. 2010;7(5):574–583. doi:10.1177/1740774510369350.
   Google Scholar
• Foster JC, Taylor JMG, Ruberg SJ. Subgroup identification from randomized clinical trial data. Stat Med. 2011;30(24):2867–2880. doi:10.1002/sim.4322.
   Google Scholar
• Athey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci USA. 2016;113(27):7353–7360. doi:10.1073/pnas.1510489113.
   Google Scholar
• Basu A, Heckman JJ, Navarro-Lozano S, et al. Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients. Health Econ. 2007;16(11):1133–1157. doi:10.1002/hec.1291.
   Google Scholar
• Xie Y, Brand JE, Jann B. Estimating Heterogeneous treatment effects with observational data. Sociol Methodol. 2012;42(1):314–347. doi: 10.1177/0081175012452652
   Google Scholar
• Trikalinos TA, Ioannidis JP. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. J Clin Epidemiol. 2001;54(3):245–252. doi: 10.1016/S0895-4356(00)00311-5
   Google Scholar
• Ioannidis JP, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. Am J Epidemiol. 1998;148(11):1117–1126. doi: 10.1093/oxfordjournals.aje.a009590
   Google Scholar
• Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283(7):889–896. doi: 10.1001/jama.283.7.889
   Google Scholar
• Kent DM, Vijan S, Hayward RA, et al. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. J Clin Epidemiol. 2004;57(8):843–852. doi:10.1016/j.jclinepi.2004.01.008.
   Google Scholar